|
1
|
Shay JW and Wright WE: Role of telomeres
and telomerase in cancer. Semin Cancer Biol. 21:349–353. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nabetani A and Ishikawa F: Alternative
lengthening of telomeres pathway: Recombination-mediated telomere
maintenance mechanism in human cells. J Biochem. 149:5–14. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Griewank KG, Murali R, Schilling B, Scholz
S, Sucker A, Song M, Süsskind D, Grabellus F, Zimmer L, Hillen U,
et al: TERT promoter mutations in ocular melanoma distinguish
between conjunctival and uveal tumours. Br J Cancer. 109:497–501.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin
L and Garraway LA: Highly recurrent TERT promoter mutations in
human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu D, Dwyer J, Li H, Duan W and Liu JP:
Ets2 maintains hTERT gene expression and breast cancer cell
proliferation by interacting with c-Myc. J Biol Chem.
283:23567–23580. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Remke M, Ramaswamy V, Peacock J, Shih DJ,
Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, et
al: TERT promoter mutations are highly recurrent in SHH subgroup
medulloblastoma. Acta Neuropathol. 126:917–929. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weiss WA, Aldape K, Mohapatra G,
Feuerstein BG and Bishop JM: Targeted expression of MYCN causes
neuroblastoma in transgenic mice. EMBO J. 16:2985–2995. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pugh TJ, Morozova O, Attiyeh EF,
Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M,
Kiezun A, et al: The genetic landscape of high-risk neuroblastoma.
Nat Genet. 45:279–284. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Molenaar JJ, Koster J, Zwijnenburg DA, van
Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J,
Westerman BA, van Arkel J, et al: Sequencing of neuroblastoma
identifies chromothripsis and defects in neuritogenesis genes.
Nature. 483:589–593. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheung NK, Zhang J, Lu C, Parker M,
Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, et
al: St Jude Children's Research Hospital-Washington University
Pediatric Cancer Genome Project: Association of age at diagnosis
and genetic mutations in patients with neuroblastoma. JAMA.
307:1062–1071. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Poremba C, Scheel C, Hero B, Christiansen
H, Schaefer KL, Nakayama Ji, Berthold F, Juergens H, Boecker W and
Dockhorn-Dworniczak B: Telomerase activity and telomerase subunits
gene expression patterns in neuroblastoma: A molecular and
immunohistochemical study establishing prognostic tools for
fresh-frozen and paraffin-embedded tissues. J Clin Oncol.
18:2582–2592. 2000.PubMed/NCBI
|
|
14
|
Brodeur GM and Bagatell R: Mechanisms of
neuroblastoma regression. Nat Rev Clin Oncol. 11:704–713. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mac SM, D'Cunha CA and Farnham PJ: Direct
recruitment of N-myc to target gene promoters. Mol Carcinog.
29:76–86. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schulte JH, Horn S, Otto T, et al: MYCN
regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer.
122:699–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cobrinik D, Ostrovnaya I, Hassimi M,
Tickoo SK, Cheung IY and Cheung NK: Recurrent pre-existing and
acquired DNA copy number alterations, including focal TERT gains,
in neuroblastoma central nervous system metastases. Genes
Chromosomes Cancer. 52:1150–1166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vandesompele J, De Preter K, Pattyn F, et
al: Accurate normalization of real-time quantitative RT-PCR data by
geometric averaging of multiple internal control genes. Genome
Biol. 3:RESEARCH0034. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bachmann HS, Heukamp LC, Schmitz KJ, et
al: Regulatory BCL2 promoter polymorphism (−938C>A) is
associated with adverse outcome in patients with prostate
carcinoma. International journal of cancer. Int J Cancer.
129:2390–2399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sadée W, Yu VC, Richards ML, Preis PN,
Schwab MR, Brodsky FM and Biedler JL: Expression of
neurotransmitter receptors and myc protooncogenes in subclones of a
human neuroblastoma cell line. Cancer Res. 47:5207–5212.
1987.PubMed/NCBI
|
|
21
|
Barnes EN, Biedler JL, Spengler BA and
Lyser KM: The fine structure of continuous human neuroblastoma
lines SK-N-SH, SK-N-BE(2) and SK-N-MC. In Vitro. 17:619–631. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Biedler JL, Helson L and Spengler BA:
Morphology and growth, tumorigenicity and cytogenetics of human
neuroblastoma cells in continuous culture. Cancer Res.
33:2643–2652. 1973.PubMed/NCBI
|
|
23
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lindsey JC, Schwalbe EC, Potluri S, Bailey
S, Williamson D and Clifford SC: TERT promoter mutation and
aberrant hypermethylation are associated with elevated expression
in medulloblastoma and characterise the majority of non-infant SHH
subgroup tumours. Acta Neuropathol. 127:307–309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Papathomas TG, Oudijk L, Zwarthoff EC,
Post E, Duijkers FA, van Noesel MM, Hofland LJ, Pollard PJ, Maher
ER, Restuccia DF, et al: Telomerase reverse transcriptase promoter
mutations in tumors originating from the adrenal gland and
extra-adrenal paraganglia. Endocr Relat Cancer. 21:653–661. 2014.
View Article : Google Scholar : PubMed/NCBI
|
